DE4212122A1 - Low calorie food contg. fat, carbohydrate, protein, calcium salt and vitamin=D - is used for prevention of osteoporosis before bone metabolism leads to pronounced loss of bone material - Google Patents
Low calorie food contg. fat, carbohydrate, protein, calcium salt and vitamin=D - is used for prevention of osteoporosis before bone metabolism leads to pronounced loss of bone materialInfo
- Publication number
- DE4212122A1 DE4212122A1 DE4212122A DE4212122A DE4212122A1 DE 4212122 A1 DE4212122 A1 DE 4212122A1 DE 4212122 A DE4212122 A DE 4212122A DE 4212122 A DE4212122 A DE 4212122A DE 4212122 A1 DE4212122 A1 DE 4212122A1
- Authority
- DE
- Germany
- Prior art keywords
- protein
- food according
- vitamin
- bone
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 21
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 title claims abstract description 7
- 230000002265 prevention Effects 0.000 title claims abstract description 6
- 210000000988 bone and bone Anatomy 0.000 title abstract description 22
- 230000004097 bone metabolism Effects 0.000 title abstract 2
- 239000000463 material Substances 0.000 title abstract 2
- 159000000007 calcium salts Chemical class 0.000 title description 4
- 229940088594 vitamin Drugs 0.000 title description 3
- 229930003231 vitamin Natural products 0.000 title description 3
- 235000013343 vitamin Nutrition 0.000 title description 3
- 239000011782 vitamin Substances 0.000 title description 3
- 150000003722 vitamin derivatives Chemical class 0.000 title description 2
- 235000005911 diet Nutrition 0.000 claims abstract description 18
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 8
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 8
- 239000011710 vitamin D Substances 0.000 claims abstract description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 8
- 229940046008 vitamin d Drugs 0.000 claims abstract description 8
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 6
- 230000037213 diet Effects 0.000 claims abstract description 5
- 239000003925 fat Substances 0.000 claims abstract description 5
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 3
- 238000000554 physical therapy Methods 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 238000012549 training Methods 0.000 claims abstract description 3
- 230000000378 dietary effect Effects 0.000 claims description 13
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 235000001465 calcium Nutrition 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 235000019197 fats Nutrition 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- 102000014171 Milk Proteins Human genes 0.000 claims description 3
- 108010011756 Milk Proteins Proteins 0.000 claims description 3
- 230000035622 drinking Effects 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 235000021239 milk protein Nutrition 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 3
- 229940081974 saccharin Drugs 0.000 claims description 3
- 235000019204 saccharin Nutrition 0.000 claims description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 3
- 239000011775 sodium fluoride Substances 0.000 claims description 3
- 235000013024 sodium fluoride Nutrition 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 claims description 2
- 229940109275 cyclamate Drugs 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 2
- 239000011565 manganese chloride Substances 0.000 claims description 2
- 235000002867 manganese chloride Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 235000007715 potassium iodide Nutrition 0.000 claims description 2
- 235000004252 protein component Nutrition 0.000 claims description 2
- 239000011684 sodium molybdate Substances 0.000 claims description 2
- 235000015393 sodium molybdate Nutrition 0.000 claims description 2
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 229960001763 zinc sulfate Drugs 0.000 claims description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 235000000053 special nutrition Nutrition 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000005486 microgravity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 206010065687 Bone loss Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010016818 Fluorosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000037176 bone building Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 239000011636 chromium(III) chloride Substances 0.000 description 1
- 235000007831 chromium(III) chloride Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000004042 dental fluorosis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 229940083626 folic acid 0.4 mg Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000011328 necessary treatment Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940089133 vitamin b6 5 mg Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
- A23J3/08—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Bei Osteoporose handelt es sich um eine Knochenerkrankung, bei der es zu einem quantitativen Verlust an Knochensubstanz in Form der mineralischen Komponente, hauptsächlich von Calciumphoshpat und anderen Calciumsalzen und zu einem pathologisch ausgeprägten Mangel an Calcium in der Knochenmatrix kommt.Osteoporosis is a bone disease that it to a quantitative loss of bone in the form of mineral component, mainly from calcium phosphate and other calcium salts and to a pathologically pronounced deficiency Calcium comes in the bone matrix.
Da diesen Substanzen in erster Linie die Härte und Dichte des Knochengewebes zuzuschreiben ist, führt deren quantitative Minderung zwangsläufig zu einer Abnahme der Gesamtskelettmasse und einer erheblich gesteigerten Anfälligkeit gegenüber Knochenfrakturen insbesondere des Handgelenks, der Wirbelsäule, aber auch des Oberschenkels. Der zugrunde liegende krankhafte Prozeß führt allerdings nicht nur zu einem verminderten Mineralanteil, sondern insgesamt zu einer Reduzierung der organischen Grundsubstanz beim pathologisch veränderten Knochen.Because these substances primarily the hardness and density of the Bone tissue is attributable to their quantitative reduction inevitably lead to a decrease in total skeletal mass and one significantly increased susceptibility to bone fractures especially the wrist, the spine, but also the Thigh. The underlying pathological process leads however not only to a reduced mineral content, but overall to a reduction in the organic base substance in pathologically altered bones.
Normalerweise ist bei gesunden Erwachsenen die Geschwindigkeit, mit der Osteoklasten und Osteoblasten gebildet werden so definiert, daß die Knochenbildung und Knochenresorption im Gleichgewicht stehen, dieses jedoch bis zu einem gewissen Grade vom Alter der betreffenden Personen abhängt. Bei Osteoporotikern jedoch entwickelt sich ein Ungleichgewicht beim Knochenumwandlungsprozeß durch das der Knochenschwund schneller vonstatten geht als die Knochenbildung.Usually, in healthy adults, the rate at which Osteoclasts and osteoblasts are defined so that the Bone formation and bone resorption are in balance, this however up to depends to a certain extent on the age of the person concerned. However, an imbalance develops in osteoporotic patients in the bone transformation process through which the bone loss is faster than bone formation.
Man nimmt an, daß im Rahmen eines natürlichen Alterungsprozesses vom dreißigsten Lebensjahr an die Knochenresorption bei beginnendem physiologischen Abbau geringfügig überwiegt.It is believed that as part of a natural aging process from at the age of thirty at the beginning of bone resorption physiological degradation predominates slightly.
Sie tritt im jüngeren Alter bei Osteoporotikern auf, insbesondere bei denjenigen, die die postmenopausale Form des Befalls entwickeln. Die Aufmerksamkeit der mit der Bekämpfung der Osteoporose befaßten Forschung ist daher zum nicht geringen Teil auf die Vorbeugung bzw. Verhinderung der postmenopausalen Osteoporose gerichtet, wobei wenigstens eine Verminderung oder Verlangsamung des Abbaus von Knochen erreicht werden soll.It occurs at a younger age in osteoporotic patients, in particular those who develop the postmenopausal form of the infestation. The Attention to those involved in combating osteoporosis Research is therefore to a large extent on prevention or Prevention of postmenopausal osteoporosis, whereby at least a reduction or slowdown in bone breakdown should be achieved.
Mit unterschiedlichen Methoden ist versucht worden, die Knochenaktivierung durch kontinuierliche Verabreichung von anorganischem Phosphat zu induzieren und getrennt die Knochen resorption durch absatzweise Verabreichung von Calcitonin zu inhibieren. Wie sich dabei zeigte, führte diese Methode bei Patienten mit postmenopausaler Osteoporose zu einer Nettoknochenbildung. Außerdem wurde ein Lösungsansatz vorgeschlagen, der davon ausgeht, daß es möglich sein müßte, die Knochenzellenaktivität und den Metabolismus zu synchronisieren durch Verabreichung von Knochen aktivierenden Mitteln. Nach der Synchronisation sollte es dann möglich sein, die Resorption durch Verabreichung eines Knochenresorptionsinhibierungs mittels während der natürlichen Lebensdauer der Resorptionsphase der Knochenumwandlungseinheit zu begrenzen. Dieses Modell spricht jedoch nicht das Problem der Knochenformungsinhibierung an, die bekanntermaßen mit der Verabreichung eines Knochenresorptionsmittels verbunden ist.Attempts have been made with different methods to achieve that Bone activation through continuous administration of to induce inorganic phosphate and separate the bones absorption by batch administration of calcitonin inhibit. As it turned out, this method led to patients with postmenopausal osteoporosis for a net bone formation. A solution has also been proposed that assumes that it should be possible for bone cell activity and metabolism to synchronize by administering bone activating Means. After synchronization, it should then be possible to Absorption by administering a bone resorption inhibitor means during the natural life of the absorption phase Limit bone conversion unit. However, this model speaks does not address the problem of bone formation inhibition as is known with the administration of a bone resorbent connected is.
Es hat sich gezeigt, daß die Zuführung von physiologisch akzeptablen Calciumsalzen nicht mit einem therapeutischen Effekt verknüpft ist. Dagegen ist eine Reihe von Substanzen, darunter Vitamin A, Heparin, Glucosamin, bekannt, die die Calciumresorption entweder allein oder in Verbindung mit Calciumsalzen verbessern sollen. Mit einer verbesserten Ca-Resorption aus der Nahrung ist jedoch nicht zwangsläufig eine signifikant gesteigerte Knochenformation verbunden. Die mit der Anwendung solcher Substanzen erzielten Wirkungen lassen sich nur über langwierige Behandlungsserien und hohe Dosen erreichen, sie sind häufig nicht von nachhaltiger Dauer.It has been shown that the supply of physiologically acceptable Calcium salts are not linked to a therapeutic effect. In contrast, a number of substances, including vitamin A, heparin, Glucosamine, known to cause calcium absorption either alone or in To improve connection with calcium salts. With an improved Ca absorption from food is not necessarily one significantly increased bone formation. The one with the The effects of such substances can only be achieved using lengthy treatment series and high doses, they are often not of lasting duration.
Auch ist bekannt, daß hohe Gaben von Natriumfluorid in Richtung einer Neubildung von Knochensubstanz zu wirken vermögen, wobei es zu einer allmählichen Mineralisierung im Knochen kommen kann. Die Verabreichung entsprechend hoher Mengen an Fluoriden - sei es in reiner Form, sei es in Verbindung mit anderweitigen Verbindungen - kann zudem nicht nur periostale Schmerzen und toxische Erscheinungen ähnlich denen bei Fluorose nach sich ziehen, sondern auch zu einem Brüchigwerden der Knochen führen.It is also known that high doses of sodium fluoride are towards one New bone formation are able to act, resulting in a gradual mineralization in the bone can occur. The administration correspondingly high amounts of fluorides - be it in pure form or be it in connection with other connections - not only can periosteal pain and toxic symptoms similar to those in Cause fluorosis, but also to break the Lead bones.
Es sind ferner therapeutische Mittel wie z. B. Östrogen-Präparate, Vitamin D, anorganische Phosphate, Calcitonin u. a. bekannt, mit deren Hilfe versucht wurde, das Fortschreiten der Knochenresorption zu verlangsamen. In der Regel konnten hierdurch bei manifester Osteoporose nur vorübergehende Veränderungen im Sinne einer Besserung erzielt werden.There are also therapeutic agents such. B. estrogen preparations, Vitamin D, inorganic phosphates, calcitonin u. a. known with their Help was sought to advance bone resorption slow it down. As a rule, this could result in manifest Osteoporosis only temporary changes in the sense of improvement be achieved.
Es sind bisher viele Versuche durchgeführt worden, um Osteoporose mit pharmakologischen Mitteln zu behandeln, wobei das Ziel entweder lautete, den weiteren Knochenschwund zu verlangsamen oder einen Nettozuwachs der Knochenmasse zu realisieren. Zwar sind Mittel bekannt, die den weiteren Knochenschwund bei Osteoporotikern reduzieren, jedoch zeigt sich daß die Mittel oder Methoden zur Behandlung, die zum Ersatz von Knochen führen, der bereits geschwunden ist, sehr unzuverlässig wirken. Der Grund dafür liegt wahrscheinlich in den engen Interdependenzen der Knochenumwandlung. Mittel oder Behandlungsmethoden, die eine Phase des Zyklus (entweder Resorption oder Bildung) stimulieren oder unterdrücken, neigen dazu, die gleiche Wirkung auf den umgekehrten Prozeß zu haben. Deshalb führten die meisten Anstrengungen zur Behandlung von Osteoporose lediglich zu einer vorübergehenden Veränderung und wenn der umgekehrte Prozeß stimuliert oder unterdrückt wird, wird diese Veränderung wieder aufgehoben.There have been many attempts to treat osteoporosis to treat pharmacological agents, the goal being either was to slow down further bone loss or one Realize net increase in bone mass. They are means known to further bone loss in osteoporotics reduce, but it turns out that the means or methods for Treatment that leads to the replacement of bone that has already shrunk is very unreliable. The reason for this is probably in the narrow interdependencies of bone transformation. Means or Treatment methods that involve a phase of the cycle (either absorption or education) stimulate or suppress, tend to be the same To have an effect on the reverse process. Therefore, the most efforts to treat osteoporosis are simply too a temporary change and if the reverse process is stimulated or suppressed, this change will happen again canceled.
Die bisher in Verbindung mit einer Medikation in Betracht gezogenen Substanzen sind weniger auf vorbeugende, eher auf Maßnahmen zur Bekämpfung und Beeinflussung bereits manifester Osteoporose gerichtet. Bei Wissenschaftlern und Ärzten hat sich inzwischen die Erkenntnis durchgesetzt, daß als Grundlage aller Maßnahmen gegen die Entwicklung einer Osteoporose eine knochengesunde Lebensweise und Ernährung anzustreben sei. Eine solche knochengesunde Lebensweise kann zwar gezielte ärztliche Maßnahmen gegen die Ursachen der Osteoporose nicht ersetzen, vermag diese aber wirkungsvoll zu ergänzen. Über Art, Umfang, Durchführung einer knochenbewußten Ernährung bestand bislang eine beträchtliche Unsicherheit bei Interessierten und Betroffenen. Spezielle Diätvorschriften beeinträchtigen gewöhnlich bestimmte Ernährungsgewohnheiten erheblich, die sich im Laufe eines Lebens eingebürgert haben können, und werden daher oft nicht konsequent genug durchgeführt. Zusätzliche Medikationen in Form von Tabletten im Rahmen von Vorbeugungsmaßnahmen werden meist abgelehnt und oft nur widerwillig in Verbindung mit ärztlich notwendigen Behandlungs maßnahmen akzeptiert.The previously considered in connection with medication Substances are less for preventive, rather for measures to be taken Combating and influencing manifest osteoporosis. Scientists and doctors have now come to realize this enforced that as the basis of all measures against development osteoporosis is a healthy lifestyle and nutrition should be aimed at. Such a healthy bone lifestyle can targeted medical measures against the causes of osteoporosis do not replace, but can effectively supplement them. About Art, The extent and implementation of a bone-conscious diet existed so far considerable uncertainty among those who are interested and affected. Special dietary regulations usually affect certain Dietary habits that change significantly over a lifetime may have naturalized, and are therefore often not consistent enough carried out. Additional medications in the form of tablets in the frame preventive measures are mostly rejected and often only reluctantly in connection with medically necessary treatment measures accepted.
Der Erfindung liegt daher die Aufgabe zugrunde, ein wirksames Mittel zu finden, das geeignet ist, ärztliche wie nichtärztliche gegen Osteoporose gerichtete Maßnahmen bereits in einer Phase zu unterstützen, in der es im Metabolismus des Knochenumwandlungs prozesses noch nicht zu einem ausgeprägten Ungleichgewicht zugunsten eines Knochenschwundes gekommen ist, das zugleich aber auch als ergänzende, bilanzierende Diät im Rahmen beispielsweise von Physiotherapie- und Trainingsprogrammen zur Bekämpfung der Osteroporose bei Erwachsenen mit Erfolg eingesetzt werden kann.The invention is therefore based on the object of being an effective means to find that is suitable, both medical and non-medical against Measures aimed at osteoporosis already in one phase support in the metabolism of bone transformation process to a pronounced imbalance in favor of a bone loss, but also as supplementary, balancing diet within the framework of, for example, Physiotherapy and training programs to combat Easter oporosis can be used successfully in adults.
Es wurde jedoch überraschenderweise gefunden, daß die erfindungsgemäße
gleichzeitige Anwendung der Komponenten einen synergistischen Effekt
ergibt. Nunmehr wird nämlich zur sinnvollen Therapie der Osteoporose
sowohl dem Schwund der anorganischen Knochensubstanz, als auch der
Verminderung der organischen Grundsubstanz des Knochens entgegenge
wirkt, wobei das Agens neben geringen Mengen Fetten und Kohlehydraten
ein Eiweiß-Calcium-Konzentrat in Verbindung mit Vitamin D in folgenden
Mengenverhältnissen enthält:
50 g Eiweiß,
100-2000 mg Calcium in Form des Salzes
einer physiologisch genehmen
Säure,
1,25-15 µg Vitamin D.However, it has surprisingly been found that the simultaneous use of the components according to the invention results in a synergistic effect. Now, for the sensible therapy of osteoporosis, both the loss of the inorganic bone substance and the reduction of the organic basic substance of the bone are counteracted, whereby the agent, in addition to small amounts of fats and carbohydrates, a protein-calcium concentrate in combination with vitamin D in the following proportions contains:
50 g protein,
100-2000 mg calcium in the form of the salt of a physiologically acceptable acid,
1.25-15 µg vitamin D.
Als Eiweißkomponente ist erfindungsgemäß ein Instant-Eiweißkonzentrat, z. B. ein Milch- oder Molkeneiweiß handelsüblicher Art vorgesehen. Als Calciumträger erwies sich Calciumcitrat u. a. als geeignet.According to the invention, an instant protein concentrate is the protein component, e.g. B. a milk or whey protein commercially available type. As Calcium carrier proved calcium citrate u. a. as suitable.
Das erfindungsgemäße Mittel enthält wenig Fett und Kohlehydrate, letztere ganz oder teilweise in Form von Fructose.The agent according to the invention contains little fat and carbohydrates, the latter in whole or in part in the form of fructose.
Zur besonderen Ernährung bei Diabetes können Süßstoffe wie "Cyclamat" oder "Saccharin", weiterhin natürliche und naturidentische Aromastoffe, Trennmittel, Carbonate und Emulgatoren - beispielsweise Lecithin - Bestandteil des erfindungsgemäßen Mittels sein.As a special diet in diabetes, sweeteners such as "cyclamate" or "saccharin", still natural and nature-identical flavorings, Release agents, carbonates and emulsifiers - e.g. lecithin - Be part of the agent according to the invention.
Dieses zeichnet sich ferner durch einen Gehalt an den Vitaminen A, D, E, K, B₁, B₂, B₆, B₁₂, C, Niacin, Folsäure, Pantothensäure sowie von Spurenelementen wie Eisen, Zink, Kupfer, Jod, Chrom, Mangan, Molybdän und Fluorid aus.This is also characterized by a content of vitamins A, D, E, K, B₁, B₂, B₆, B₁₂, C, niacin, folic acid, Pantothenic acid and trace elements such as iron, zinc, copper, iodine, Chromium, manganese, molybdenum and fluoride.
Das erfindungsgemaße Instant-Eiweißkonzentrat eignet sich gut zur Zubereitung einer Trinknahrung zur ergänzenden Ernährung für Heranwachsende und Erwachsene. Es stellt damit eine mit Vitaminen und Spurenelementen bilanzierte Nahrungsergänzung zur Verfügung, die insbesondere bei hohem Eiweiß- und Calciumbedarf, nicht jedoch gemeinsam mit anderweitigen herkömmlichen Nahrungsmitteln zu verabreichen ist, welches jedoch nicht für Infusionen geeignet ist.The instant protein concentrate according to the invention is well suited for Preparation of a drinking food for supplementary nutrition for Adolescents and adults. It provides one with vitamins and Trace nutritional supplements available that especially with high protein and calcium requirements, but not along with other conventional foods is administered, which is not suitable for infusions.
Anhand eines Ausführungsbeispiels soll der Erfindungsgegenstand näher erläutert werden.The subject of the invention is intended to be explained in more detail using an exemplary embodiment are explained.
Je 100 g verzehrfertiger Zubereitung (Trockenform) werden eingesetzt
Milcheiweiß (80%ig) 80,0 g,
Calciumcitrat 4,74 g,
Vitamin D 30 µg,
Vitamin C 200 mg,
Nicotinsäureamid 24 mg,
Vitamin E 16 mg,
Pantothensäure 16 mg,
Vitamin B₆ 5 mg,
Vitamin B₂ 2,4 mg,
Vitamin b₁ 2 mg,
Vitamin A 1,6 mg,
Folsäure 0,4 mg,
Biotin 180 µg,
Vitamin K₁ 80 µg,
Vitamin B₁₂ 8 µg,
Eisen(II)-sulfat 52,2 mg,
Zinksulfat 27,4 mg,
Mangan(II)-chlorid 17,3 mg,
Kupfer(II)-sulfat 9,4 mg,
Natriumfluorid 5,3 mg,
Kaliumjodid 470 µg,
Natriummolybdat 360 µg,
Chrom (III)-chlorid 50 µg.100 g ready-to-eat preparations (dry form) are used
Milk protein (80%) 80.0 g,
Calcium citrate 4.74 g,
Vitamin D 30 µg,
Vitamin C 200 mg,
Nicotinamide 24 mg,
Vitamin E 16 mg,
Pantothenic acid 16 mg,
Vitamin B₆ 5 mg,
Vitamin B₂ 2.4 mg,
Vitamin b 1 2 mg,
Vitamin A 1.6 mg,
Folic acid 0.4 mg,
Biotin 180 µg,
Vitamin K₁ 80 µg,
Vitamin B₁₂ 8 µg,
Iron (II) sulfate 52.2 mg,
Zinc sulfate 27.4 mg,
Manganese (II) chloride 17.3 mg,
Copper (II) sulfate 9.4 mg,
Sodium fluoride 5.3 mg,
Potassium iodide 470 µg,
Sodium molybdate 360 µg,
Chromium (III) chloride 50 µg.
Der Restanteil ist gebildet aus natürlichen und naturidentischen Aromastoffen, einem herkömmlichen Emulgator (Lecithin), einem Trennmittel (z. B. Magnesiumcarbonat) sowie den Süßstoffen "Cyclamat" und "Saccharin".The remainder is made up of natural and nature-identical ones Flavorings, a conventional emulsifier (lecithin), a Release agent (e.g. magnesium carbonate) and the sweetener "Cyclamat" and "saccharin".
Zur Verabreichung sind beispielsweise 25 g dieses Konzentrats ohne zu kochen in 250 ml Flüssigkeit, vorzugsweise Wasser oder Milch, einzurühren. Unter Berücksichtigung der jeweils dann zusätzlich gegebenen Nähr- bzw. Brennwerte ist auch ein Zusatz zu anderen Getränken oder Speisen, z. B. Joghurt, möglich.For administration, for example, 25 g of this concentrate are without boil in 250 ml of liquid, preferably water or milk, to stir. Taking into account each additional then given nutritional or calorific values is also an addition to others Drinks or food, e.g. B. yogurt possible.
In Form einer ergänzenden bilanzierten Diät ist der Verzehr von zwei Portionen zu je 25 g, also 50 g Konzentrat (Pulver) als Trinknahrung zubereitet, ausreichend. Eine derartig zubereitete eiweißreiche Nahrungsergänzung ist jedoch zum sofortigen Verzehr bestimmt; sie kann dann allenfalls im dicht verschlossenen Behältnis in einem Kühlschrank bis zu 12 Stunden aufbewahrt werden.Consuming two is in the form of a supplementary balanced diet Portions of 25 g each, i.e. 50 g concentrate (powder) as drinking food prepared, sufficient. A protein-rich prepared in this way However, food supplements are intended for immediate consumption; she can then at most in a tightly closed container in a refrigerator can be kept for up to 12 hours.
Das erfindungsgemäße diätetische Lebensmittel hat sich nicht nur im Rahmen der Unterstützung ärztlicher Maßnahmen gegen Osteoporose als überaus wirksam erwiesen, es vermag naturgemäß auch wesentlich zum Ausgleich eines Mangels an Eiweiß, Calcium und Vitamin D bei Jugendlichen in der Phase des Knochenaufbaus und darüber hinaus bei gesunden Erwachsenen zur Prävention gegenüber Verlusten an Knochenmineralgehalt beizutragen. Mit dem erfindungsgemäßen diätetischen Konzentrat ist damit gesunden Erwachsen wie Jungendlichen, aber auch bereits an Osteoporose Erkrankten eine Antwort auf die bei der Vorsorge und Behandlung in Bezug auf diese Krankheit immer wieder gestellte Frage: " . . . und was kann ich selbst tun?" gegeben.The dietary food according to the invention has not only in the As part of the support of medical measures against osteoporosis as proven to be extremely effective, it is naturally also capable of Compensation for a lack of protein, calcium and vitamin D. Adolescents in the bone building phase and beyond healthy adults to prevent loss Contribute bone mineral content. With the invention dietary concentrate is like healthy adults Adolescents, but also those already suffering from osteoporosis Answer to those in the prevention and treatment related to this Illness repeatedly asked question: "... And what can I do myself do? "given.
Claims (9)
50 g Eiweiß,
100-2000 m g Calcium in Form des Salzes einer physiologisch genehmen Säure,
1,25-15 µg Vitamin D.1. Dietary low-calorie food to support medical and non-medical measures against osteoporosis, for example for the prevention of postmenopausal osteoporosis, characterized in that it contains, in addition to fats and carbohydrates, an protein, calcium concentrate and vitamin D in the following proportions:
50 g protein,
100-2000 mg calcium in the form of the salt of a physiologically acceptable acid,
1.25-15 µg vitamin D.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4212122A DE4212122C2 (en) | 1992-04-10 | 1992-04-10 | Dietary low-energy food to support medical and non-medical measures against osteoporosis |
DE9218438U DE9218438U1 (en) | 1992-04-10 | 1992-04-10 | Dietary low-calorie food to support medical and non-medical measures against osteoporosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4212122A DE4212122C2 (en) | 1992-04-10 | 1992-04-10 | Dietary low-energy food to support medical and non-medical measures against osteoporosis |
Publications (2)
Publication Number | Publication Date |
---|---|
DE4212122A1 true DE4212122A1 (en) | 1993-10-14 |
DE4212122C2 DE4212122C2 (en) | 1999-07-29 |
Family
ID=6456578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE4212122A Expired - Fee Related DE4212122C2 (en) | 1992-04-10 | 1992-04-10 | Dietary low-energy food to support medical and non-medical measures against osteoporosis |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE4212122C2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6908630B2 (en) * | 2000-08-01 | 2005-06-21 | Metaproteomics, Llc | Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3097947A (en) * | 1961-01-30 | 1963-07-16 | Mend Johnson & Company | Nutritional composition and process |
DE2621215A1 (en) * | 1975-05-16 | 1976-12-02 | Alan Norman Dr Howard | DIAL COMPOSITION |
WO1986003380A1 (en) * | 1984-12-10 | 1986-06-19 | Boehringer Biochemia S.P.A. | Dietetic compositions |
GB2169485A (en) * | 1985-01-15 | 1986-07-16 | Abneycrest Limited | A formulation for use in treating obesity |
EP0259167A2 (en) * | 1986-09-05 | 1988-03-09 | Phillip Lowell Millman | Nutrient composition for athletes and method of making and using the same |
JPS6421A (en) * | 1987-02-27 | 1989-01-05 | Teijin Ltd | Preventive for osteoporosis |
EP0300895A1 (en) * | 1987-07-23 | 1989-01-25 | Nb International Technologies | Food mixture for the elderly |
EP0478792A1 (en) * | 1990-04-06 | 1992-04-08 | Otsuka Pharmaceutical Co., Ltd. | High-protein high-viscosity alimentary food composition |
-
1992
- 1992-04-10 DE DE4212122A patent/DE4212122C2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3097947A (en) * | 1961-01-30 | 1963-07-16 | Mend Johnson & Company | Nutritional composition and process |
DE2621215A1 (en) * | 1975-05-16 | 1976-12-02 | Alan Norman Dr Howard | DIAL COMPOSITION |
WO1986003380A1 (en) * | 1984-12-10 | 1986-06-19 | Boehringer Biochemia S.P.A. | Dietetic compositions |
GB2169485A (en) * | 1985-01-15 | 1986-07-16 | Abneycrest Limited | A formulation for use in treating obesity |
EP0259167A2 (en) * | 1986-09-05 | 1988-03-09 | Phillip Lowell Millman | Nutrient composition for athletes and method of making and using the same |
JPS6421A (en) * | 1987-02-27 | 1989-01-05 | Teijin Ltd | Preventive for osteoporosis |
EP0300895A1 (en) * | 1987-07-23 | 1989-01-25 | Nb International Technologies | Food mixture for the elderly |
EP0478792A1 (en) * | 1990-04-06 | 1992-04-08 | Otsuka Pharmaceutical Co., Ltd. | High-protein high-viscosity alimentary food composition |
Non-Patent Citations (3)
Title |
---|
Diätverband: Grüne Liste 1992 - Aulendorf: Editio-Cantor-Verlag 1992, Produkt-Nr. 16008, Nr. 16030, 08003, 14006, 03031 * |
GALLWAS, K.: Prävention systemischer Osteoporosen und Osteoporomalazien. In: Z. Alternsforsch. 42 (1987), S. 33-39 * |
KRÄMER, K.-L., et. al.: Klinikleitfaden Orthopädie, 1. Auflage, Neckarsulm, Stuttgart: Jungjohann Verlagsgesellschaft 1992, S. 302-307 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6908630B2 (en) * | 2000-08-01 | 2005-06-21 | Metaproteomics, Llc | Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2 |
Also Published As
Publication number | Publication date |
---|---|
DE4212122C2 (en) | 1999-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69233250T2 (en) | COMBINATIONS OF CALCIUM AND VITAMIN D | |
DE69110130T2 (en) | ACCESSORIES FROM CALCIUM AND TRACE ELEMENTS. | |
DE69703839T2 (en) | COMPOSITION SUITABLE AS A FOOD OR TO LOWER THE SERUM LIPID LEVEL | |
DE60207877T2 (en) | Composition containing procyanidins for reducing appetite in mammals | |
DE69122025T2 (en) | Nutritious composition | |
AU666654B2 (en) | Calcium, trace mineral, vitamin D and drug therapy combinations | |
EP0755633B1 (en) | Two phases preparation | |
DE60027303T2 (en) | APPROVAL METHOD | |
DE3875867T2 (en) | CALCIUM ADDITIVES. | |
DE2530372A1 (en) | Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts. | |
DE3880587T2 (en) | USE OF CERTAIN CALCIUM-CITRATE MALATES FOR THE PRODUCTION OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF OSTEOPOROSIS. | |
EP2152101A1 (en) | Milk fat-milk protein composition (preferably esterified with palmitic acid) for improving calcium absorption | |
DE60103055T2 (en) | NUTRITIONAL SUPPLEMENT FOR IMPROVING MUSCLE ENERGY METABOLISM, CONTAINING ALKANOYL-CARNITINE AND RIBOSE | |
DE4413839C1 (en) | Prepn. to protect human bodies from oxidative processes | |
EP0198172B1 (en) | Pharmaceutical preparation | |
DE4405545A1 (en) | Oral vitamin compsn. with improved resorption | |
DE69806393T2 (en) | COMPOSITION TO RELIEVE HEAT STRESS | |
DE60124516T2 (en) | COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID | |
DE4212122C2 (en) | Dietary low-energy food to support medical and non-medical measures against osteoporosis | |
EP0098975B1 (en) | Biostimulating drug | |
DE9412374U1 (en) | Food supplements | |
DE202004013660U1 (en) | Vitamin-containing product for nutritional supplementation, useful in cases of cardiovascular disease, also promotes bone formation | |
DE9218438U1 (en) | Dietary low-calorie food to support medical and non-medical measures against osteoporosis | |
EP0374935B1 (en) | Preparation for preventing osteoporosis and for treating osteoporosis | |
DE19534602C2 (en) | Use of threonine to treat phenylketonuria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
8125 | Change of the main classification |
Ipc: A23L 1/29 |
|
D2 | Grant after examination | ||
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: NURITUR GMBH, 78464 KONSTANZ, DE |
|
8381 | Inventor (new situation) |
Free format text: HESCH, ROLF-DIETER, PROF.DR.MED., 78464 KONSTANZ, DE |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: HESCH, OLIVER, PARIS, FR |
|
8339 | Ceased/non-payment of the annual fee |